• Rhythm has entered a non-exclusive ColoSTAT® Product Distribution Service Agreement with 4Cyte Pathology
• 4Cyte will integrate ColoSTAT® into its clinical ordering system across over 1,000 patient collection centres
• 4Cyte will support patient sample collection and transport to Rhythm's lab for analysis

Rhythm Biosciences Ltd (ASX:RHY), a predictive cancer diagnostics technology company, has entered into a ColoSTAT® Distribution Service Agreement with 4Cyte Pathology Pty Ltd, one of Australia's largest independent pathology providers. Under the agreement, 4Cyte will integrate ColoSTAT® into its clinical ordering system across its network of over 1,000 patient collection centres in New South Wales, Victoria, and Queensland. 4Cyte will support patient sample collection through its phlebotomy network, with serum samples transported to the Rhythm ISO 15189-accredited laboratory in Parkville, Victoria for analysis. Results will then be delivered back to the referring healthcare practitioner via 4Cyte's established reporting systems. Rhythm will perform the testing and invoice patients directly, with no upfront payments or minimum volume commitments required from either party. The partnership provides Rhythm with access to an established clinical ordering and specimen collection network, reducing operational barriers for healthcare practitioners to order the ColoSTAT® test. Key benefits include immediate access to over 1,000 patient collection centres, leverage of 4Cyte's existing phlebotomy and logistics infrastructure, and complementary promotional capability through 4Cyte's clinical engagement. The agreement is a capital-efficient, variable-cost structure aligned with Rhythm's early commercialisation phase.

The partnership positions ColoSTAT® to be accessed through established pathology workflows and potentially address the unmet need for alternative colorectal cancer screening pathways in Australia, where screening participation remains below 50%.